BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10401183)

  • 1. [Action of SERM and SAS (tibolone) on breast tissue].
    Gompel A; Jacob D; de Chambine S; Mimoun M; Decroix Y; Rostene W; Poitout P
    Contracept Fertil Sex; 1999 May; 27(5):368-75. PubMed ID: 10401183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Searching for the ideal SERM.
    Poletti A
    Pharmacol Res; 1999 May; 39(5):333. PubMed ID: 10328989
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Sem Hop; 1984 Mar; 60(10):703-9. PubMed ID: 6322320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors].
    Jovanović-Mićić D; Beleslin DB; Nikolić SS
    Med Pregl; 1996; 49(7-8):287-90. PubMed ID: 8926945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-estrogens, selective estrogen receptor modulators (SERM), tibolone: modes of action].
    Maudelonde T; Brouillet JP; Pujol P
    Contracept Fertil Sex; 1999 Sep; 27(9):620-4. PubMed ID: 10540506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Sgroi DC; Haber DA; Ryan PD; Ma XJ; Erlander MG
    Cancer Cell; 2004 Nov; 6(5):445. PubMed ID: 15542428
    [No Abstract]   [Full Text] [Related]  

  • 12. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted antiestrogens.
    Tonetti DA; Jordan VC
    Prog Clin Biol Res; 1997; 396():245-55. PubMed ID: 9108602
    [No Abstract]   [Full Text] [Related]  

  • 15. [Anti-hormonal therapy in breast cancer].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 1994 Aug; 17(8):247-50. PubMed ID: 7935152
    [No Abstract]   [Full Text] [Related]  

  • 16. [New developments in the hormonal treatment of breast cancer in postmenopausal women].
    Trunet P; Marty M
    Bull Cancer; 1999 Oct; 86(10):815-20. PubMed ID: 10572232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
    Thomas S; Munster PN
    Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.
    Fichtner I; Becker M; Zeisig R; Sommer A
    Eur J Cancer; 2004 Apr; 40(6):845-51. PubMed ID: 15120040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiestrogens: mechanism of action and clinical applications].
    Barrón-González A; Arias-Martínez J; Castro-Romero I
    Salud Publica Mex; 2001; 43(6):577-84. PubMed ID: 11816234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment.
    Marcsek Z; Kocsis Z; Jakab M; Szende B; Tompa A
    Cancer Biother Radiopharm; 2004 Dec; 19(6):746-53. PubMed ID: 15665622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.